Clinical trials: REC-617
Phase 1b, Open Label
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
- Conditions
- Phase 1b, Open Label, REC-617, RB1-Negative
- Trial name
- NCT07633756
- Testing
- REC617
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center